PCMTD2 Inhibitors
PCMTD2 inhibitors are a class of chemical compounds that target and inhibit protein-L-isoaspartyl methyltransferase domain-containing protein 2 (PCMTD2), an enzyme involved in the repair of damaged proteins. PCMTD2 functions by recognizing and catalyzing the methylation of isoaspartyl residues, which are formed as a result of the spontaneous deamidation or isomerization of asparagine or aspartic acid residues in proteins. This process helps to restore the correct protein conformation and maintain protein stability and function, thereby playing a critical role in protein quality control and the prevention of protein aggregation. Inhibitors of PCMTD2 interfere with this repair mechanism, disrupting the enzyme's ability to maintain protein integrity in cells.
The mechanism of PCMTD2 inhibitors involves binding to the enzyme's active site or interfering with its interaction with substrates, preventing the methylation of damaged proteins. This inhibition can lead to the accumulation of misfolded or damaged proteins, offering a useful tool for researchers studying protein homeostasis, aging, and the effects of protein damage on cellular function. By blocking PCMTD2 activity, scientists can explore how cells cope with protein damage and the broader implications of protein repair mechanisms in maintaining cellular health. These inhibitors help provide insights into the role of post-translational modifications in protein maintenance, uncovering the intricate balance between protein synthesis, repair, and degradation that is essential for normal cellular function. The study of PCMTD2 inhibitors contributes to our understanding of protein quality control systems and their impact on cellular metabolism and aging processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing cAMP levels that enhance Protein Name activity by stimulating cAMP-dependent protein kinase A (PKA), which phosphorylates and activates Protein Name. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, elevates intracellular cAMP, which in turn activates PKA. PKA activation results in phosphorylation and enhancement of Protein Name activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX, a non-selective inhibitor of phosphodiesterases, prevents cAMP degradation, thereby sustaining PKA activation and subsequent phosphorylation of Protein Name, enhancing its function. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 engages with its G-protein-coupled receptor, leading to cAMP accumulation and PKA-mediated phosphorylation of Protein Name, which enhances its activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase 3 (GSK-3), a negative regulator in the Wnt/β-catenin pathway, which can lead to the stabilization and activation of β-catenin, indirectly enhancing Protein Name activity if Protein Name is part of this pathway. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, boosting cAMP production and activating PKA, which can phosphorylate and enhance Protein Name if it is a PKA substrate. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine is a substrate for nitric oxide synthase, producing nitric oxide which activates guanylyl cyclase, increasing cGMP levels and potentially enhancing Protein Name activity through cGMP-dependent protein kinases if Protein Name is part of this signaling cascade. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, increasing cGMP levels which can enhance Protein Name activity through cGMP-dependent protein kinases if Protein Name is a target of this pathway. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil, like Sildenafil, is a phosphodiesterase type 5 inhibitor, which can increase cGMP levels and potentially enhance Protein Name via cGMP-dependent protein kinases. | ||||||